Fadare, et al. [7]

50

Clear cell carcinomas

- Recurrence 73% in p53 positive group (P < 0.008)

- PFS 56 vs. 88 months (P < 0.01)

- OS 63 vs. 83 months (P = 0.07)

Garg, et al.[9]

35

Endometrioid endometrial carcinomas

- 3-year PFS 52% vs. 94% (P = 0.02)

- 3-year DSS 54% vs. 100% (P < 0.003)

Catasus, et al.[10]

132

Endometrial carcinomas

- (77%) endometrioid adenocarcinomas

- (11%) non-endometrioid adenocarcinomas

- (12%) mixed endometrioid adenocarcinomas-non-endometrioid

adenocarcinomas

- Kaplan-Meier Survival Analysis (P = 0.000)

Huvila, et al. [11]

306

Endometrioid endometrial carcinomas

- A 30-fold risk of dying of disease in high-risk group compared

to low-risk group

Obata, et al. [12]

154

Endometrioid endometrial carcinomas

- Recurrence or Metastasis

- Grade 1-2: 37.8% vs. 5.3% (P < 0.01)

- PFS 61.1% vs. 21.9% (P < 0.01).